137 related articles for article (PubMed ID: 35335898)
1. Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2.
Xu T; Zhang J; Oroujeni M; Tretyakova MS; Bodenko V; Belousov MV; Orlova A; Tolmachev V; Vorobyeva A; Gräslund T
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335898
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.
Ding H; Altai M; Rinne SS; Vorobyeva A; Tolmachev V; Gräslund T; Orlova A
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31416167
[TBL] [Abstract][Full Text] [Related]
3. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution.
Ding H; Xu T; Zhang J; Tolmachev V; Oroujeni M; Orlova A; Gräslund T; Vorobyeva A
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33806887
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.
Yin W; Xu T; Altai M; Oroujeni M; Zhang J; Vorobyeva A; Vorontsova O; Vtorushin SV; Tolmachev V; Gräslund T; Orlova A
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834389
[TBL] [Abstract][Full Text] [Related]
5. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model.
Xu T; Ding H; Vorobyeva A; Oroujeni M; Orlova A; Tolmachev V; Gräslund T
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396753
[TBL] [Abstract][Full Text] [Related]
6. Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.
Rinne SS; Yin W; Borras AM; Abouzayed A; Leitao CD; Vorobyeva A; Löfblom J; Ståhl S; Orlova A; Gräslund T
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740315
[TBL] [Abstract][Full Text] [Related]
7. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
Garousi J; Xu T; Liu Y; Vorontsova O; Hober S; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015242
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
[TBL] [Abstract][Full Text] [Related]
9. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
10. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
11. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
12. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein.
Garousi J; Ding H; von Witting E; Xu T; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Gräslund T; Tolmachev V
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834262
[TBL] [Abstract][Full Text] [Related]
13. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
[TBL] [Abstract][Full Text] [Related]
14. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
16. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
[TBL] [Abstract][Full Text] [Related]
17. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
18. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
19. Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis.
Liu Y; Güler R; Liao Y; Vorobyeva A; Widmark O; Meuleman TJ; Koijen A; van den Bos LJ; Naasz R; Bodenko V; Orlova A; Ekblad C; Tolmachev V; Frejd FY
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432709
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
